Lipocalyx provides leapfrog innovation for genetic research. Our Viromers® deliver the bits and pieces of DNA or RNA necessary to interfere with the genetic content of a cell. Viromers® take advantage of a viral fusion mechanism and, for the first time, translate this into polymer chemistry. As a result, we can reach into hard-to-transfect cells and enable siRNA or plasmid work there.
Lipocalyx started its marketing in Jan 2013 and announced a global network of distributors in Sep 2014.
Challenge: Transfection of resistant cells
Solution: Viromers, polymers using an Active Escape Technology
Business: Reagent provider & know-how provider around transfection, direct and distributor sales, co-developments
Technology: Active Endosome Escape for superior tranfection,
IP: Umbrella patent for Viromers, specific IP for products, trademarks
Market: Transfection market $283M, market potential for Viromers $80M
Customers: R&D in academia and industry, in particular those working with resistant or sensitive cells like primary cells or stem cells
Geography: Global Distribution
Competition: Life Technologies, offereing a one-stop solution for both siRNA and transfection is the most dominant player; strong brands, e.g.Fugene by Promega; electroporation (Lonza, BioRad) is currently used for resistant cells. Works well for plasmids, but not for siRNA.
Cell penetrating peptides may come up as competition ; in the future „downgrading“ of in vivo reagents may become a competition
Financing for Lipocalyx’s Innovative siRNA Delivery
06120 Halle (Saale)